Wen-Qing Li1, Eunyoung Cho2, Hamed Khalili3, Shaowei Wu4, Andrew T Chan5, Abrar A Qureshi2. 1. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island. Electronic address: wen-qing_li@brown.edu. 2. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 3. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island. 5. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: Rosacea is an inflammatory skin disease. Case reports have shown rosacea as a comorbidity of inflammatory bowel disease (IBD), but no epidemiologic studies have examined rosacea and risk of subsequent IBD. The association between tetracycline use and risk of IBD was assessed, but this study produced limited findings. We examined the association between rosacea, use of tetracycline, and risk of incident Crohn's disease (CD) and ulcerative colitis (UC). METHODS: We analyzed data from 96,314 participants in the Nurses' Health Study II (1991-2011). Information on IBD was confirmed by medical review. Participants were asked in 2005 about their lifetime histories of clinician-diagnosed rosacea and year of diagnosis. Information on ever use of tetracycline was collected in 1993. RESULTS: During 1,856,587 person-years (1991-2011), we identified 149 cases of CD and 215 cases of UC. Rosacea was not associated with risk of UC. In contrast, rosacea was significantly associated with increased risk of subsequent CD (hazard ratio [HR], 2.20; 95% confidence interval [CI], 1.15-4.18), which appeared particularly stronger for a longer duration after a diagnosis of rosacea (Ptrend = .01). Tetracycline use was associated with increased risk of CD (HR, 1.56; 95% CI, 1.09-2.24) and UC (HR, 1.34; 95% CI, 1.00-1.80); there was a trend toward increased risk with increased duration of use (both Ptrend < .05) (1993-2011). CONCLUSIONS: On the basis of an analysis of data from the Nurses' Health Study II, ever use of tetracycline at baseline is associated with an increased risk of CD and UC. Personal history of rosacea is associated with an increased risk of only CD.
BACKGROUND & AIMS:Rosacea is an inflammatory skin disease. Case reports have shown rosacea as a comorbidity of inflammatory bowel disease (IBD), but no epidemiologic studies have examined rosacea and risk of subsequent IBD. The association between tetracycline use and risk of IBD was assessed, but this study produced limited findings. We examined the association between rosacea, use of tetracycline, and risk of incident Crohn's disease (CD) and ulcerative colitis (UC). METHODS: We analyzed data from 96,314 participants in the Nurses' Health Study II (1991-2011). Information on IBD was confirmed by medical review. Participants were asked in 2005 about their lifetime histories of clinician-diagnosed rosacea and year of diagnosis. Information on ever use of tetracycline was collected in 1993. RESULTS: During 1,856,587 person-years (1991-2011), we identified 149 cases of CD and 215 cases of UC. Rosacea was not associated with risk of UC. In contrast, rosacea was significantly associated with increased risk of subsequent CD (hazard ratio [HR], 2.20; 95% confidence interval [CI], 1.15-4.18), which appeared particularly stronger for a longer duration after a diagnosis of rosacea (Ptrend = .01). Tetracycline use was associated with increased risk of CD (HR, 1.56; 95% CI, 1.09-2.24) and UC (HR, 1.34; 95% CI, 1.00-1.80); there was a trend toward increased risk with increased duration of use (both Ptrend < .05) (1993-2011). CONCLUSIONS: On the basis of an analysis of data from the Nurses' Health Study II, ever use of tetracycline at baseline is associated with an increased risk of CD and UC. Personal history of rosacea is associated with an increased risk of only CD.
Authors: E V Loftus; M D Silverstein; W J Sandborn; W J Tremaine; W S Harmsen; A R Zinsmeister Journal: Gastroenterology Date: 1998-06 Impact factor: 22.682
Authors: Mingfeng Zhang; Abrar A Qureshi; Renée T Fortner; Susan E Hankinson; Qingyi Wei; Li-E Wang; A Heather Eliassen; Walter C Willett; David J Hunter; Jiali Han Journal: Cancer Date: 2015-01-08 Impact factor: 6.860
Authors: M A M van Steensel; S Badeloe; V Winnepenninckx; M Vreeburg; P M Steijlen; M van Geel Journal: Exp Dermatol Date: 2008-07-12 Impact factor: 3.960
Authors: Anne Lynn S Chang; Inbar Raber; Jin Xu; Rui Li; Robert Spitale; Julia Chen; Amy K Kiefer; Chao Tian; Nicholas K Eriksson; David A Hinds; Joyce Y Tung Journal: J Invest Dermatol Date: 2015-02-19 Impact factor: 8.551
Authors: Philippe Goyette; Gabrielle Boucher; Dermot Mallon; Eva Ellinghaus; Luke Jostins; Hailiang Huang; Stephan Ripke; Elena S Gusareva; Vito Annese; Stephen L Hauser; Jorge R Oksenberg; Ingo Thomsen; Stephen Leslie; Mark J Daly; Kristel Van Steen; Richard H Duerr; Jeffrey C Barrett; Dermot P B McGovern; L Philip Schumm; James A Traherne; Mary N Carrington; Vasilis Kosmoliaptsis; Tom H Karlsen; Andre Franke; John D Rioux Journal: Nat Genet Date: 2015-01-05 Impact factor: 41.307
Authors: Linda Stein Gold; James Q Del Rosso; Leon Kircik; Neal D Bhatia; Deirdre Hooper; Walter Nahm; Iain Stuart Journal: J Clin Aesthet Dermatol Date: 2020-11-01
Authors: Chun-Han Lo; Hamed Khalili; Paul Lochhead; Mingyang Song; Emily W Lopes; Kristin E Burke; James M Richter; Andrew T Chan; Ashwin N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2020-12-05 Impact factor: 8.171
Authors: Jennifer L Aponte; Mathias N Chiano; Laura M Yerges-Armstrong; David A Hinds; Chao Tian; Akanksha Gupta; Cong Guo; Dana J Fraser; Johannes M Freudenberg; Deepak K Rajpal; Margaret G Ehm; Dawn M Waterworth Journal: Hum Mol Genet Date: 2018-08-01 Impact factor: 6.150